Angus Worthing, MD, FACR, FACP, discusses the benefits of biosimilar medicines.
Transcript:
What benefits do biosimilars offer to providers and to the healthcare system?
Biologic drugs have really revolutionized the practice [and] treatment of rheumatoid arthritis, and other autoimmune diseases, but that has come at a tremendous cost and oftentimes the price is a lack of access to drugs. So, it’s one of the things that gets me up out of bed in the morning, and what I really like my job for, is that I can see people, and diagnose them, and put a treatment plan in place that’s going to get them back to work and reduce their aching joints. But, it’s heartbreaking when people can’t get access to the drugs because they’re too expensive. The best thing that biosimilars give to providers, and also to patients, is the promise of increased access to care, so that everybody who needs one of these drugs can get on it, afford it, and have it also be affordable for society at large—that’s the benefit of biosimilars. In short, that’s the benefit of biosimilars.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.